CoChat

The Role of Genetics in Advancing Precision Medicine for Alzheimer’s Disease—A Narrative Review

Open access
Freudenberg-Hua, Yun, Li, Wentian, Davies, Peter · 2018 · Frontiers in Medicine
Cited by 74

The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.

Abstract

Alzheimer’s disease (AD) is the most common type of dementia, which has a substantial genetic component. AD affects predominantly older people. Accordingly, the prevalence of dementia has been rising as the population ages. To date, there are no effective interventions that can cure or halt the progression of AD. The only available treatments are the management of certain symptoms and consequences of dementia. The current state-of-the-art medical care for AD comprises three simple principles: prevent the preventable, achieve early diagnosis, and manage the manageable symptoms. This review provides a summary of the current state of knowledge of risk factors for AD, biological diagnostic testing and prospects for treatment. Special emphasis is given to recent advances in genetics of AD and the way genomic data may support prevention, early intervention and development of effective pharmacological treatments. Mutations in the APP, PSEN1, and PSEN2 genes cause early onset AD (EOAD) that follows a Mendelian inheritance pattern. For late onset AD (LOAD), APOE4 was identified as a major risk allele more than two decades ago. Population-based genome-wide association studies (GWAS) of late onset AD have now additionally identified common variants at roughly 30 genetic loci. Furthermore, rare variants (allele frequency <1%) that influence the risk for LOAD have been identified in several genes. These genetic advances have broadened our insights into the biological underpinnings of AD. Moreover, the known genetic risk variants could be used to identify presymptomatic individuals at risk for AD and support diagnostic assessment of symptomatic subjects. Genetic knowledge may also facilitate precision medicine. The goal of precision medicine is to use biological knowledge and other health information to predict individual disease risk, understand disease etiology, identify disease subcategories, improve diagnosis, and provide personalized treatment strategies. We discuss the potential role of genetics in advancing precision medicine for AD along with its ethical challenges. We outline strategies to implement genomics into translational clinical research that will not only improve accuracy of dementia diagnosis, thus enabling more personalized treatment strategies, but may also speed up the discovery of novel drugs and interventions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fmed.2018.00108

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 82 references

Research works printed but not linked: 67

  1. Barker, 2002, Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the state of Florida brain bank, Alzheimer Dis Assoc Disord, 16, 203, 10.1097/00002093-200210000-00001 · DOI · Paper page
  2. Prince, 2015, The burden of disease in older people and implications for health policy and practice, Lancet, 385, 549, 10.1016/S0140-6736(14)61347-7 · DOI · Paper page
  3. Ferri, 2005, Global prevalence of dementia: a Delphi consensus study, Lancet, 366, 2112, 10.1016/S0140-6736(05)67889-0 · DOI · Paper page
  4. Aronson, 2015, Building the foundation for genomics in precision medicine, Nature, 526, 336, 10.1038/nature15816 · DOI · Paper page
  5. McGaghie, 2015, Varieties of integrative scholarship: why rules of evidence, criteria, and standards matter, Acad Med, 90, 294, 10.1097/ACM.0000000000000585 · DOI
  6. Barsh, 2012, Guidelines for genome-wide association studies, PLoS Genet, 8, e1002812, 10.1371/journal.pgen.1002812 · DOI · Paper page
  7. MacArthur, 2017, The new NHGRI-EBI catalog of published genome-wide association studies (GWAS Catalog), Nucleic Acids Res, 45, D896, 10.1093/nar/gkw1133 · DOI · Paper page
  8. Alzheimer, 1907, Über eine eigenartige Erkrankung der Hirnrinde, Allgemeine Zeitschrift für Psychiatrie und Psychisch-Gerichtliche Medizin, 64, 146
  9. McKhann, 2011, The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease, Alzheimers Dement, 7, 263, 10.1016/j.jalz.2011.03.005 · DOI · Paper page
  10. Walsh, 1990, Survival of outpatients with Alzheimer-type dementia, Ann Intern Med, 113, 429, 10.7326/0003-4819-113-6-429 · DOI · Paper page
  11. Mirra, 1991, The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease, Neurology, 41, 479, 10.1212/WNL.41.4.479 · DOI · Paper page
  12. Sperling, 2011, Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease, Alzheimers Dement, 7, 280, 10.1016/j.jalz.2011.03.003 · DOI · Paper page
  13. Albert, 2011, The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease, Alzheimers Dement, 7, 270, 10.1016/j.jalz.2011.03.008 · DOI · Paper page
  14. Rosenberg, 2001, Dementia with Lewy bodies and Alzheimer’s disease, Acta Neuropathol, 102, 621, 10.1007/s004010100415 · DOI
  15. Cholerton, 2016, Precision medicine: clarity for the complexity of dementia, Am J Pathol, 186, 500, 10.1016/j.ajpath.2015.12.001 · DOI
  16. Schindler, 2015, Autosomal dominant Alzheimer disease: a unique resource to study CSF biomarker changes in preclinical AD, Front Neurol, 6, 142, 10.3389/fneur.2015.00142 · DOI
  17. Zhu, 2015, Rate of early onset Alzheimer’s disease: a systematic review and meta-analysis, Ann Transl Med, 3, 38, 10.3978/j.issn.2305-5839.2015.01.19 · doi:10.3978/j.issn.2305-5839.2015.01.19 · Paper page
  18. Jarmolowicz, 2015, The patterns of inheritance in early-onset dementia: Alzheimer’s disease and frontotemporal dementia, Am J Alzheimers Dis Other Demen, 30, 299, 10.1177/1533317514545825 · DOI · Paper page
  19. An, 2016, A genetic screen of the mutations in the Korean patients with early-onset Alzheimer’s disease, Clin Interv Aging, 11, 1817, 10.2147/CIA.S116724 · DOI
  20. Goate, 1991, Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease, Nature, 349, 704, 10.1038/349704a0 · DOI · Paper page
  21. Sherrington, 1995, Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease, Nature, 375, 754, 10.1038/375754a0 · DOI · Paper page
  22. Weggen, 2012, Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer’s disease, Alzheimers Res Ther, 4, 9, 10.1186/alzrt107 · DOI · Paper page
  23. Sun, 2017, Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of Abeta42 and Abeta40 peptides by gamma-secretase, Proc Natl Acad Sci U S A, 114, E476, 10.1073/pnas.1618657114 · DOI · Paper page
  24. Maloney, 2014, Molecular mechanisms of Alzheimer disease protection by the A673T allele of amyloid precursor protein, J Biol Chem, 289, 30990, 10.1074/jbc.M114.589069 · DOI · Paper page
  25. Klunk, 2004, Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B, Ann Neurol, 55, 306, 10.1002/ana.20009 · DOI · Paper page
  26. Aizenstein, 2008, Frequent amyloid deposition without significant cognitive impairment among the elderly, Arch Neurol, 65, 1509, 10.1001/archneur.65.11.1509 · DOI · Paper page
  27. Musiek, 2015, Three dimensions of the amyloid hypothesis: time, space and ‘wingmen’, Nat Neurosci, 18, 800, 10.1038/nn.4018 · DOI · Paper page
  28. Strittmatter, 1993, Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease, Proc Natl Acad Sci U S A, 90, 1977, 10.1073/pnas.90.5.1977 · DOI · Paper page
  29. Corder, 1993, Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families, Science, 261, 921, 10.1126/science.8346443 · DOI · Paper page
  30. Bickeboller, 1997, Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex, Am J Hum Genet, 60, 439
  31. Freudenberg-Hua, 2014, Disease variants in genomes of 44 centenarians, Mol Genet Genomic Med, 2, 438, 10.1002/mgg3.86 · DOI · Paper page
  32. Zhao, 2018, Apolipoprotein E, receptors, and modulation of Alzheimer’s disease, Biol Psychiatry, 83, 347, 10.1016/j.biopsych.2017.03.003 · DOI · Paper page
  33. Naj, 2010, Dementia revealed: novel chromosome 6 locus for late-onset Alzheimer disease provides genetic evidence for folate-pathway abnormalities, PLoS Genet, 6, e1001130, 10.1371/journal.pgen.1001130 · DOI · Paper page
  34. Ridge, 2016, Assessment of the genetic variance of late-onset Alzheimer’s disease, Neurobiol Aging, 41, 200.e13, 10.1016/j.neurobiolaging.2016.02.024 · DOI · Paper page
  35. Freudenberg-Hua, 2016, Differential burden of rare protein truncating variants in Alzheimer’s disease patients compared to centenarians, Hum Mol Genet, 25, 3096, 10.1093/hmg/ddw150 · DOI
  36. Van Der Lee, 2015, PLD3 variants in population studies, Nature, 520, E2, 10.1038/nature14038 · DOI
  37. Fernandez, 2017, Analysis of neurodegenerative Mendelian genes in clinically diagnosed Alzheimer disease, PLoS Genet, 13, e1007045, 10.1371/journal.pgen.1007045 · DOI
  38. Heilmann, 2015, PLD3 in non-familial Alzheimer’s disease, Nature, 520, E3, 10.1038/nature14039 · DOI
  39. Hooli, 2015, PLD3 gene variants and Alzheimer’s disease, Nature, 520, E7, 10.1038/nature14040 · DOI
  40. Lambert, 2015, PLD3 and sporadic Alzheimer’s disease risk, Nature, 520, E1, 10.1038/nature14036 · DOI · Paper page
  41. Guerreiro, 2013, SnapShot: genetics of Alzheimer’s disease, Cell, 155, 968, 10.1016/j.cell.2013.10.037 · DOI
  42. Heneka, 2015, Innate immunity in Alzheimer’s disease, Nat Immunol, 16, 229, 10.1038/ni.3102 · DOI · Paper page
  43. Wang, 2015, TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model, Cell, 160, 1061, 10.1016/j.cell.2015.01.049 · DOI · Paper page
  44. Ma, 2016, Expression and processing analyses of wild type and p.R47H TREM2 variant in Alzheimer’s disease brains, Mol Neurodegener, 11, 72, 10.1186/s13024-016-0137-9 · DOI · Paper page
  45. Warde-Farley, 2010, The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function, Nucleic Acids Res, 38, W214, 10.1093/nar/gkq537 · DOI · Paper page
  46. Li, 2015, Principles for the organization of gene-sets, Comput Biol Chem, 59, 139, 10.1016/j.compbiolchem.2015.04.005 · DOI
  47. Purcell, 2009, Common polygenic variation contributes to risk of schizophrenia and bipolar disorder, Nature, 460, 748, 10.1038/nature08185 · DOI · Paper page
  48. Wray, 2013, Pitfalls of predicting complex traits from SNPs, Nat Rev Genet, 14, 507, 10.1038/nrg3457 · DOI · Paper page
  49. Lautenschlager, 2008, Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial, JAMA, 300, 1027, 10.1001/jama.300.9.1027 · DOI · Paper page
  50. Zhou, 2017, Association between exercise and the risk of dementia: results from a nationwide longitudinal study in China, BMJ Open, 7, e017497, 10.1136/bmjopen-2017-017497 · DOI · Paper page
  51. Barreto, 2017, Exercise training for preventing dementia, mild cognitive impairment, and clinically meaningful cognitive decline: a systematic review and meta-analysis, J Gerontol A Biol Sci Med Sci, 10.1093/gerona/glx234 · DOI · Paper page
  52. Espeland, 2017, Effect of a long-term intensive lifestyle intervention on prevalence of cognitive impairment, Neurology, 88, 2026, 10.1212/WNL.0000000000003955 · DOI · Paper page
  53. Katan, 1986, Apolipoprotein E isoforms, serum cholesterol, and cancer, Lancet, 1, 507, 10.1016/S0140-6736(86)92972-7 · DOI · Paper page
  54. Cataldo, 2010, Cigarette smoking is a risk factor for Alzheimer’s disease: an analysis controlling for tobacco industry affiliation, J Alzheimers Dis, 19, 465, 10.3233/JAD-2010-1240 · DOI · Paper page
  55. Thomas, 2010, Gene–environment-wide association studies: emerging approaches, Nat Rev Genet, 11, 259, 10.1038/nrg2764 · DOI · Paper page
  56. Carroll, 2017, Another Alzheimer’s drug flops in pivotal clinical trial, Science, 10.1126/science.aal0759 · DOI
  57. Gold, 2017, Phase II clinical trials of anti-amyloid beta antibodies: when is enough, enough?, Alzheimers Dement (N Y), 3, 402, 10.1016/j.trci.2017.04.005 · DOI · Paper page
  58. Giacobini, 2013, Alzheimer disease therapy – moving from amyloid-beta to tau, Nat Rev Neurol, 9, 677, 10.1038/nrneurol.2013.223 · DOI · Paper page
  59. Reiman, 2016, CAP – advancing the evaluation of preclinical Alzheimer disease treatments, Nat Rev Neurol, 12, 56, 10.1038/nrneurol.2015.177 · DOI · Paper page
  60. Reitz, 2016, Toward precision medicine in Alzheimer’s disease, Ann Transl Med, 4, 107, 10.21037/atm.2016.03.05 · DOI · Paper page
  61. Blennow, 2015, Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer’s disease, Alzheimers Dement, 11, 58, 10.1016/j.jalz.2014.02.004 · DOI · Paper page
  62. Mittal, 2017, beta2-Adrenoreceptor is a regulator of the alpha-synuclein gene driving risk of Parkinson’s disease, Science, 357, 891, 10.1126/science.aaf3934 · DOI · Paper page
  63. Phillips, 2016, Only a click away – DTC genetics for ancestry, health, love … and more: a view of the business and regulatory landscape, Appl Transl Genom, 8, 16, 10.1016/j.atg.2016.01.001 · DOI · Paper page
  64. Defesche, 2017, Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia, J Clin Lipidol, 11, 1338, 10.1016/j.jacl.2017.08.016 · DOI · Paper page
  65. Crane, 2017, Alzheimer’s disease sequencing project discovery and replication criteria for cases and controls: data from a community-based prospective cohort study with autopsy follow-up, Alzheimers Dement, 13, 1410, 10.1016/j.jalz.2017.09.010 · DOI
  66. Mapes, 2017, How should clinicians counsel a woman with a strong family history of early-onset Alzheimer’s disease about her pregnancy?, AMA J Ethics, 19, 663, 10.1001/journalofethics.2017.19.7.ecas4-1707 · DOI
  67. Caulfield, 2013, Harm, hype and evidence: Elsi research and policy guidance, Genome Med, 5, 21, 10.1186/gm425 · DOI

Cited by

See all 74

Metadata

Authors
Freudenberg-Hua, Y., Li, W., & Davies, P.
Venue
Frontiers in Medicine
Published
2018-04-24
Volume
5
Pages
108-108
ISSN
2296-858X (ISSN-L)
OpenAlex
W2802923338
Cited by
74
References
82
FWCI
1.41
Type
journal article
Language
en
Open access
gold
Funders
National Institutes of Health (1K08AG054727-01A1)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Role of Genetics in Advancing Precision Medicine for Alzheimer’s Disease—A Narrative Review. https://app.cochat.ai/papers/10.3389/fmed.2018.00108
The paper
Freudenberg-Hua, Y., Li, W., & Davies, P. (2018). The Role of Genetics in Advancing Precision Medicine for Alzheimer’s Disease—A Narrative Review. Frontiers in Medicine. https://doi.org/10.3389/fmed.2018.00108

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.